Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

NCT ID: NCT04252612

Last Updated: 2023-06-28

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: EARLY_PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-30
• Study Completion Date: 2023-06-26

Brief Summary

This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.

Conditions

Cutaneous Squamous Cell Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1: Pramlintide 60 mcg twice daily

Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.

Group Type: EXPERIMENTAL

Pramlintide

Intervention Type: DRUG

SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Cohort 2: Pramlintide 60 mcg three times daily

Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.

Group Type: EXPERIMENTAL

Pramlintide

Intervention Type: DRUG

SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Cohort 3: Pramlintide 120 mcg three times daily

Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.

Group Type: EXPERIMENTAL

Pramlintide

Intervention Type: DRUG

SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Interventions

Pramlintide

SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.

Intervention Type: DRUG

Other Intervention Names

Symlin; SymlinPen

Eligibility Criteria

Inclusion Criteria

• Histologically proven cutaneous squamous cell carcinoma. Mixed histologies (basaloid, spindle, sarcomatoid, etc.) are allowed if the pathology review favors squamous cell carcinoma as the majority component. Cancers of unknown primary sites are allowed if the clinical history and the site are highly suggestive of a skin cancer primary
• Tumor site must be amenable for surgical resection and accessible for pre-treatment biopsy
• Tumor site must be measurable by caliper measurements or by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 imaging - lesions must be ≥1 cm
• Eastern Cooperative Oncology Group (ECOG) ≤2 and be medically able to undergo surgical resection
• Laboratory Requirements: Hemoglobin ≥ 8 g/dl, Platelet count ≥ 50,000/dl, Serum Creatinine ≤ 1.5 mg/dL OR Glomular Filtration Rate (GFR) ≥ 40, Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) < 2.5x ULN; Total Bilirubin < 1.5x ULN (for patients with documented history of Gilbert's syndrome, total bilirubin level should be < 3.0 X ULN)
• Ability to understand and willingness to sign a written informed consent document
• Patients with child bearing potential must be willing to use barrier protection to prevent pregnancy while on study therapy and up to 30 days after the last dose of pramlintide
• Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Patients must be willing to comply with the protocol for the duration of the treatment including daily sub-cutaneous (SQ) injections, biopsies, scheduled visits and examinations, radiologic studies, and surgical resection

Exclusion Criteria

• Type I diabetes: Type II diabetics (DM2) on insulin are allowed, however, for those DM2 patients that are on short acting insulin, the insulin dose should be reduced 50% and need to have regular glucose monitoring (see section 6.2.1). Type II diabetics not on insulin will not be eligible.
• Patients with known gastroparesis
• Patients with known allergic reactions to pramlintide or its ingredients
• Pregnant women and/or nursing patients will be excluded from this study because of unknown risks to fetus or nursing infants
• Any serious or uncontrolled medical disorder that could interfere with the current study as deemed by the investigating physician
• Participation in any other clinical study using an investigational agent within 21 days of starting treatment on this protocol
• No prior chemotherapy, radiation, or other tumor directed therapy within 21 days prior of starting treatment on this protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

H. Lee Moffitt Cancer Center and Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nikhil Khushalani, MD

Role: PRINCIPAL_INVESTIGATOR

Moffitt Cancer Center

Locations

Moffitt Cancer Center

Tampa, Florida, United States

Countries

United States

Other Identifiers

MCC-19708

Identifier Type: -

Identifier Source: org_study_id